3 results
Our primary objective is to investigate the effects of endotoxin-induced systemic inflammation and subsequent development of endotoxin tolerance on the inflammatory response following Fluenz® administration in vivo. To evaluate whether these effects…
Primary:To evaluate the clinical efficacy of nemiralisib compared with placebo to reduce the annual rate of moderate and severe exacerbations in participants with COPD.Secondary:Further efficacy parameters pertaining to exacerbations and aligned…
1. To improve the overall outcome as compared to the previous protocols of the DCOG, especially ALL-9 and ALL-10.This is aimed for by decreasing therapy for part of the patients (TEL/AML1, Down syndrome, PPR only), increasing therapy for IKZF1…